870 related articles for article (PubMed ID: 17303969)
21. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
Joshi GP; Gertler R; Fricker R
Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
[TBL] [Abstract][Full Text] [Related]
23. Adverse Drug Events Involving COX-2 Inhibitors.
Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
[TBL] [Abstract][Full Text] [Related]
24. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
25. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
26. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Zhao SZ; Wentworth C; Burke TA; Makuch RW
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
[TBL] [Abstract][Full Text] [Related]
27. Are rofecoxib and celecoxib safer NSAIDS?
Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
29. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
30. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
Fredy J; Diggins DA; Morrill GB
Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
32. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
Fung HB; Kirschenbaum HL
Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513
[TBL] [Abstract][Full Text] [Related]
33. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
Brophy JM; Lévesque LE; Zhang B
Heart; 2007 Feb; 93(2):189-94. PubMed ID: 16849374
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
35. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
36. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
37. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Dai C; Stafford RS; Alexander GC
Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
[TBL] [Abstract][Full Text] [Related]
38. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
Moride Y; Ducruet T; Rochon S; Lavoie F
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
[TBL] [Abstract][Full Text] [Related]
39. New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study.
Wang J; Mullins CD; Mamdani M; Rublee DA; Shaya FT
Ann Pharmacother; 2007 Jun; 41(6):937-43. PubMed ID: 17488830
[TBL] [Abstract][Full Text] [Related]
40. [COX-2 inhibitors--one step forward and two steps back].
Evensen S; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]